Skunkworx Bio is pioneering a new generation of precision medicines through its innovative approach that combines biology with advanced computational design. The company focuses on developing "Pocket Biologics," which are therapeutics derived from extensive libraries of antibodies and small proteins. By integrating computational and bioinformatic analyses into their drug discovery process, Skunkworx aims to accelerate the transition from discovery to preclinical development. Their unique methodology emphasizes the identification of pharmacologically active sites on proteins, known as HotSpots, which are critical for understanding protein-protein interactions and developing targeted therapeutics.

The versatility of Skunkworx's Pocket Biologics allows for the differentiation of disease-relevant HotSpots, enabling the rapid development of validated drug leads that can function as either agonists or antagonists. The company employs a multifaceted platform that includes high-diversity, randomized Pocket Protein libraries and fully human Pocket Antibody libraries. This approach not only facilitates the identification of novel drug targets but also enhances the specificity and efficacy of therapeutic candidates. Skunkworx Bio's commitment to integrating wet lab design with computational biology positions it at the forefront of innovative biologics for various diseases, including cancer, and highlights its potential for next-generation drug targeting strategies.

United States

Skunkworx Bio (SKWX) is a drug discovery powerhouse obsessed with building novel therapeutics for major unmet medical needs.  SKWX expertise comes from two decades of molecular engineering experience with leaders in the field of biologic intervention.  The company’s unique and proprietary technical platform allows for the generation of new biological entities unknown to biology and outside the human repertoire of possibilities.    

Skunkworx Bio

Company Details